A5023909576- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Neuroendocrine Tumor Research Advances
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Treatments and Mutations
- Pancreatitis Pathology and Treatment
- Renal cell carcinoma treatment
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Surgical Treatments
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Colorectal and Anal Carcinomas
- Colorectal Cancer Screening and Detection
- Esophageal Cancer Research and Treatment
- Gallbladder and Bile Duct Disorders
- Esophageal and GI Pathology
- Cancer Cells and Metastasis
- Liver Disease Diagnosis and Treatment
- Liver physiology and pathology
- Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
Université Libre de Bruxelles
2013-2024
Erasmus Hospital
2015-2024
Mie University Hospital
1998-2024
Weatherford College
2007-2021
Institut Jules Bordet
2009-2020
Centre Hospitalier Interrégional Edith Cavell
2020
Service de la Santé Publique
2020
Philipps University of Marburg
2019
Université Paris Cité
2016
Fédération Francophone de Cancérologie Digestive
2016
<h3>Importance</h3> In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial and efficacy erlotinib unknown. <h3>Objectives</h3> To assess whether improves overall survival patients with cancer controlled after 4 months gemcitabine-based induction chemotherapy to effect on survival. <h3>Design, Setting, Participants</h3> LAP07, an international, open-label, phase 3 randomized trial, 449 were enrolled between 2008 2011. Follow-up ended in February 2013....
Treatment with gemcitabine provides modest benefits in patients metastatic pancreatic cancer. The addition of erlotinib to shows a small but significant improvement overall survival (OS) versus alone. Phase II results for bevacizumab plus provided the rationale phase III trial gemcitabine-erlotinib or placebo.Patients adenocarcinoma were randomly assigned receive (1,000 mg/m(2)/week), (100 mg/day), and (5 mg/kg every 2 weeks) gemcitabine, erlotinib, placebo this double-blind, trial. Primary...
Background:Positive findings from the phase III MPACT trial led to regulatory approval of nab-paclitaxel plus gemcitabine as a treatment option for patients with metastatic pancreatic cancer. This report is an update overall survival (OS) based on longer follow-up.
Purpose The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall (OS) benefit adjuvant oxaliplatin stage II to III resected colon cancer. This update presents 10-year OS DFS by mismatch repair (MMR) status BRAF mutation. Methods Survival actualization after follow-up was performed 2,246 patients with We assessed MMR mutation 1,008 formalin-fixed...
Liver dissemination is a major cause of mortality among patients with advanced colorectal cancer. Hepatic intra-arterial injection the beta-emitting isotope yttrium-90 ((90)Y) bound to resin microspheres (radioembolization) delivers therapeutic radiation doses liver metastases minimal damage adjacent tissues.We conducted prospective, multicenter, randomized phase III trial in unresectable, chemotherapy-refractory liver-limited metastatic CRC (mCRC) comparing arm A (fluorouracil [FU]...
AIM:To evaluate the ability of endoscopic ultrasound (EUS) elastography to distinguish benign from malignant pancreatic masses and lymph nodes. METHODS:A multicenter study was conducted included 222 patients who underwent EUS examination with assessment a mass (n = 121) or node 101).The classification as malignant, based on real time pattern, compared B-mode images final diagnosis obtained by EUS-guided fine needle aspiration (EUS-FNA) and/or surgical pathology.An interobserver performed....
The prognostic value of BRAF and KRAS mutations within microsatellite-unstable (MSI) microsatellite-stable (MSS) subgroups resected colon carcinoma patients remains controversial. We examined this question in prospectively collected biospecimens from stage III cancer with separate analysis MSI MSS tumors receiving adjuvant FOLFOX +/- cetuximab two therapy trials.
<h3>BACKGROUND</h3> Eradication of Barrett9s mucosa by thermal or photoablation combined with high doses proton pump inhibitors is a potentially attractive strategy in the management this preneoplastic condition. However, major concerns method are persistence residual metaplastic glands beneath new squamous epithelium and absence any knowledge its impact on long term outcome. <h3>CASE REPORT</h3> The case an intramucosal adenocarcinoma diagnosed 18 months after apparently complete...
The role of the anti–inflammatory cytokine interleukin–10 (IL–10) was investigated in mouse model liver injury induced by carbon tetrachloride (CCl 4 ). To address endogenous IL–10 production, acute hepatitis CCl C57Bl/6 gene knock out (KO) and wild–type (WT) mice. After challenge, serum levels tumor necrosis factor–alpha (TNF–α) transforming growth factor–beta 1 (TGF–β1) increased were significantly higher KO mice, whereas IL–6 only slightly compared with WT At histological examination,...
Gemcitabine is a promising adjuvant treatment for patients with resected pancreatic adenocarcinoma and its use in combination radiotherapy under exploration. Human equilibrative nucleoside transporter 1 (hENT1) human concentrative (hCNT) 3 are the major transporters responsible 2',2'-difluoro-2-deoxycytidine (gemcitabine) uptake into cells. The aim of this study was to determine patients' outcome according expression hENT1 hCNT3 tumoral cells after postoperative gemcitabine-based...
The prognostic value of BRAF and KRAS mutations in patients who have undergone resection for colon cancer been treated with combination leucovorin, fluorouracil, oxaliplatin (FOLFOX)-based adjuvant chemotherapy is controversial, possibly owing to a lack stratification on mismatch repair status.To examine the effect stage III FOLFOX or without cetuximab.This study included available tumor blocks resected adenocarcinoma participated between December 2005 November 2009 PETACC-8 phase randomized...